GRI Bio shares are trading lower after the company announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 in patients with idiopathic pulmonary fibrosis.

Benzinga Newsdesk www.benzinga.com Negative 96.7%

Neg 96.7% Neu 0% Pos 0%

Comments

No comments yet. Be the first!